Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Ardelyx, Inc. faces hurdles with Xphozah's reimbursement, expenses, and its pipeline, raising concerns about profitability ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

Investing.com-- Bank of America (BofA) analysts highlighted several Japanese stocks as top picks following strong ...

Others run the gamut from Sanofi’s T cell receptor–targeting amlitelimab for atopic dermatitis, with a 52-week data readout expected in March, to the microRNA-targeting obefazimod from Paris-based ...

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...

Elite Pharmaceuticals experienced a mixed performance in Q3 2024. While quarterly revenues decreased to $14.4 million, the company reported a significant 35% increase in nine-month revenues ...

Q3 Results, Earnings Today: Today, majors like Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Alembic Pharma, Castrol India, Taj GVK Hotels & Resorts, and others are releasing their ...

SBI Q3 Results LIVE: Capital Adequacy Ratio (CAR) as at the end of Q3FY25 stands at 13.03%, shows an exchange filing. - Credit growth at 13.49% YoY with domestic advances growing by 14.06% YoY.

However, the company’s total premium surged 37 per cent to ₹1,151 crore in Q3FY25 of this fiscal against ₹841 crore in Q3 of FY24, driven by group premium which more than doubled year-on ...

Follow our LIVE blog for the latest updates. We wrap up today's edition of the Moneycontrol live Q3 earnings blog, and will be back tomorrow morning with all the latest updates and alerts.